| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | cfaB |
| Uniprot No | P0CK93 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-170aa |
| 氨基酸序列 | VEKNITVTASVDPAIDLLQADGNALPSAVKLAYSPASKTFESYRVMTQVHTNDATKKVIVKLADTPQLTDVLNSTVQMPISVSWGGQVLSTTAKEFEAAALGYSASGVNGVSSSQELVISAAPKTAGTAPTAGNYSGVVSLVMTLGS |
| 预测分子量 | 31.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CFAB重组蛋白的3篇代表性文献示例，涵盖不同研究方向：
---
1. **文献名称**：*Immunogenicity of Recombinant CfaB Protein from Enterotoxigenic E. coli in a Murine Model*
**作者**：Zhang, Y. et al.
**摘要**：研究通过原核系统表达ETEC的CfaB蛋白，证实其在小鼠模型中可诱导高滴度特异性抗体，并显著降低细菌肠道定植能力，为疫苗开发提供依据。
---
2. **文献名称**：*Optimization of Expression Conditions for Soluble CfaB in E. coli Using Taguchi Design*
**作者**：Kumar, S. & Lee, J.H.
**摘要**：采用实验设计优化重组CfaB在大肠杆菌中的可溶性表达条件，确定最佳诱导温度、IPTG浓度及培养基成分，显著提高蛋白产量至120 mg/L。
---
3. **文献名称**：*Structural Insights into CfaB-mediated Adhesion in ETEC by Cryo-EM*
**作者**：Patel, R. et al.
**摘要**：通过冷冻电镜解析重组CfaB蛋白的分子结构，揭示其与宿主肠上皮细胞受体结合的特定结构域，为抗黏附疗法提供靶点。
---
注：上述文献信息及摘要内容为示例性模拟，实际研究中建议通过PubMed、Web of Science等平台以关键词“CfaB recombinant protein”、“ETEC colonization factor”检索最新文献。
The cfaB recombinant protein is a key component in studying enterotoxigenic *Escherichia coli* (ETEC) pathogenesis and vaccine development. CfaB, a major structural subunit of colonization factor antigen I (CFA/I) fimbriae, mediates bacterial adherence to host intestinal epithelium, a critical step in ETEC infection. CFA/I fimbriae are proteinaceous appendages enabling ETEC to colonize the small intestine, facilitating toxin delivery and diarrheal disease. Recombinant cfaB is produced via genetic engineering, typically by cloning the *cfaB* gene into expression vectors (e.g., *E. coli* or yeast systems) to generate purified protein for research or immunization.
Interest in cfaB stems from its role as a protective antigen. Antibodies against cfaB block bacterial adhesion, reducing colonization and disease severity. This immunogenicity has positioned cfaB as a candidate for subunit vaccines against ETEC, a leading cause of traveler's diarrhea and pediatric mortality in low-resource regions. Structural studies reveal cfaB's conserved epitopes, supporting cross-reactive vaccine designs targeting multiple ETEC strains. Additionally, recombinant cfaB aids in elucidating fimbrial assembly mechanisms and host-pathogen interactions.
Recent advances include its incorporation into multivalent vaccine platforms alongside other colonization factors (e.g., CS6. LTB) and adjuvants to enhance immune responses. Challenges persist in ensuring stability and broad coverage across ETEC variants, but animal studies demonstrate promising efficacy. Beyond vaccines, cfaB recombinant protein serves in diagnostic kits and adhesion inhibition assays, contributing to therapeutic discovery and epidemiological surveillance. Its study remains vital for combating antibiotic-resistant ETEC strains through non-antibiotic strategies.
×
